Long-term use of indomethacin leads to poor prognoses through promoting the expression of PD-1 and PD-L2 via TRIF/NF-κB pathway and JAK/STAT3 pathway to inhibit TNF-α and IFN-γ in hepatocellular carcinoma

Experimental Cell Research

Volumn 337, Issue 1, 2015, Pages 53-60

  Xu, Pingbo ^a   Sun, Zhirong ^a   wang, Yun ^a   Miao, Changhong ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Hepatocellular carcinoma; IFN ; Indomethacin; PD 1 PD L2 pathway; TNF ; TRIF NF B

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; JANUS KINASE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; STAT3 PROTEIN; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; NONSTEROID ANTIINFLAMMATORY AGENT; PDCD1 PROTEIN, MOUSE; PDCD1LG2 PROTEIN, MOUSE; STAT3 PROTEIN, HUMAN; TICAM-1 PROTEIN, MOUSE; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR RECURRENCE; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; GENETICS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; METABOLISM; PATHOLOGY; PROGNOSIS; SECONDARY; TUMOR CELL LINE;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; INDOMETHACIN; INTERFERON-GAMMA; JANUS KINASES; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MICE, INBRED BALB C; NF-KAPPA B; PROGNOSIS; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; PROGRAMMED CELL DEATH 1 RECEPTOR; STAT3 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84939571077     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2015.07.007     Document Type: Article

References (25)

1. Shariff M.I., Cox I.J., Gomaa A.I., Khan S.A., Gedroyc W., Taylor-Robinson S.D. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev. Gastroenterol. Hepatol. 2009, 3:353-367.
2. Portolani N., Coniglio A., Ghidoni S., et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann. Surg. 2006, 243:229-235.
3. Tang Z.Y. Hepatocellular carcinoma-cause, treatment and metastasis. World J. Gastroenterol. 2001, 7:445-454.
4. Jana N.R. NSAIDs and apoptosis. Cell. Mol. Life Sci. 2008, 65:1295-1301.
5. Tenenbaum J. The epidemiology of nonsteroidal anti-inflammatory drugs. Can. J. Gastroenterol. 1999, 13:119-122.
6. Arun B., Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Sem. Oncol. 2004, 31:22-29.
7. Harris R.E., Chlebowski R.T., Jackson R.D., et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res. 2003, 63:6096-6101.
8. Ye C.G., Wu W.K., Yeung J.H., et al. Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression. Cancer Lett. 2011, 304:90-96.
9. Inaoka M., Kimishima M., Takahashi R., Shiohara T. Non-steroidal anti-inflammatory drugs selectively inhibit cytokine production by NK cells and gamma delta T cells. Exp. Dermatol. 2006, 15:981-990.
10. van Horssen R., Ten Hagen T.L., Eggermont A.M. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 2006, 11:397-408.
11. Salisbury T.B., Tomblin J.K., Primerano D.A., et al. Endogenous aryl hydrocarbon receptor promotes basal and inducible expression of tumor necrosis factor target genes in MCF-7 cancer cells. Biochem. Pharmacol. 2014, 91:390-399.
12. Boehm U., Klamp T., Groot M., Howard J.C. Cellular responses to interferon-gamma. Ann. Rev. Immunol. 1997, 15:749-795.
13. Detjen K.M., Farwig K., Welzel M., Wiedenmann B., Rosewicz S. Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut 2001, 49:251-262.
14. Olalekan S.A., Cao Y., Hamel K.M., Finnegan A. B cells expressing IFN-gamma suppress Treg-cell differentiation and promote autoimmune experimental arthritis. Eur. J. Immunol. 2015, 45:988-998.
15. Ribas A. Tumor immunotherapy directed at PD-1. N. Engl. J. Med. 2012, 366:2517-2519.
16. McDermott D.F., Atkins M.B. PD-1 as a potential target in cancer therapy. Cancer Med. 2013, 2:662-673.
17. Ghiotto M., Gauthier L., Serriari N., et al. PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int. Immunol. 2010, 22:651-660.
18. Constantinescu S.N., Girardot M., Pecquet C. Mining for JAK-STAT mutations in cancer. Trends Biochem. Sci. 2008, 33:122-131.
19. Yuan M.M., Xu Y.Y., Chen L., Li X.Y., Qin J., Shen Y. TLR3 expression correlates with apoptosis, proliferation and angiogenesis in hepatocellular carcinoma and predicts prognosis. BMC Cancer 2015, 15:245.
20. Futakuchi M., Ogawa K., Sano M., Tamano S., Takeshita F., Shirai T. Suppression of lung metastasis by aspirin but not indomethacin in an in vivo model of chemically induced hepatocellular carcinoma. Jpn. J. Cancer Res. (Gann) 2002, 93:1175-1181.
21. Zeng Z., Shi F., Zhou L., et al. Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PloS one 2011, 6:e23621.
22. Riella L.V., Paterson A.M., Sharpe A.H., Chandraker A. Role of the PD-1 pathway in the immune response. Am. J. Transplant.: Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg. 2012, 12:2575-2587.
23. Gao Q., Wang X.Y., Qiu S.J., et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2009, 15:971-979.
24. Hu Z., Ou Y., Duan K., Jiang X. Inflammation: a bridge between postoperative cognitive dysfunction and Alzheimer's disease. Med. Hypotheses 2010, 74:722-724.
25. Wei R.C., Cao X., Gui J.H., et al. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma. Hum. Gene Ther. 2011, 22:1109-1119.